EP0845043B1
(en)
*
|
1995-07-28 |
2007-06-27 |
Marie Curie Cancer Care |
Transport proteins and their uses
|
US6017735A
(en)
*
|
1997-01-23 |
2000-01-25 |
Marie Curie Cancer Care |
Materials and methods for intracellular transport and their uses
|
GB9705903D0
(en)
*
|
1997-03-21 |
1997-05-07 |
Elliott Gillian D |
VP22 Proteins and uses thereof
|
CA2291010A1
(en)
|
1997-06-02 |
1998-12-10 |
Chiron Corporation |
Herpes simplex virus vp22 vaccines and methods of use
|
DE69940805D1
(de)
|
1998-01-31 |
2009-06-10 |
Sinai School Medicine |
Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
|
GB9816761D0
(en)
|
1998-07-31 |
1998-09-30 |
Phogen Limited |
Herpesvirus preparations and their uses
|
JP2002522451A
(ja)
|
1998-08-07 |
2002-07-23 |
ユニバーシティ オブ ワシントン |
免疫学的単純ヘルペスウイルス抗原とその使用法
|
DE19845420C2
(de)
*
|
1998-10-02 |
2000-11-16 |
Deutsches Krebsforsch |
Interzelluläre Ausbreitung rekombinanter DNA
|
JP4854853B2
(ja)
*
|
1998-11-12 |
2012-01-18 |
ライフ テクノロジーズ コーポレーション |
トランスフェクション薬剤
|
US6316252B1
(en)
*
|
1998-12-17 |
2001-11-13 |
Wisconsin Alumni Research Foundation |
Biotherapeutic delivery system
|
CA2365625A1
(en)
*
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of substances to cells
|
WO2000058488A2
(en)
*
|
1999-03-31 |
2000-10-05 |
Invitrogen Corporation |
Delivery of functional protein sequences by translocating polypeptides
|
US6773920B1
(en)
|
1999-03-31 |
2004-08-10 |
Invitrogen Corporation |
Delivery of functional protein sequences by translocating polypeptides
|
WO2000061617A2
(en)
*
|
1999-04-12 |
2000-10-19 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells for use in gene therapy
|
US6451601B1
(en)
|
1999-04-12 |
2002-09-17 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells for use in gene therapy
|
US6358739B1
(en)
|
1999-04-12 |
2002-03-19 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells
|
DE19933089A1
(de)
*
|
1999-07-15 |
2001-01-18 |
Max Delbrueck Centrum |
Mittel zur Gewerbsregeneration
|
EP1210362A2
(en)
|
1999-09-01 |
2002-06-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
|
US20030219826A1
(en)
*
|
1999-09-01 |
2003-11-27 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
US20030104622A1
(en)
*
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
ATE345389T1
(de)
|
1999-09-30 |
2006-12-15 |
Univ Washington |
Immunologisch relevante antigene aus herpes simplexvirus
|
US20030108539A1
(en)
|
2000-02-14 |
2003-06-12 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
US8183339B1
(en)
|
1999-10-12 |
2012-05-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
US20040082509A1
(en)
|
1999-10-12 |
2004-04-29 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
DE19955576B4
(de)
*
|
1999-11-18 |
2008-02-28 |
Faustus Forschungs Cie. Translational Cancer Research Gmbh |
Transferverbindungen, ihre Herstellung und ihre Verwendung
|
GB9930519D0
(en)
|
1999-12-24 |
2000-02-16 |
Phogen Limited |
Uses of transport proteins
|
DE10001230A1
(de)
*
|
2000-01-13 |
2001-08-02 |
Deutsches Krebsforsch |
Immunisierungsmittel
|
US6688084B2
(en)
*
|
2000-03-24 |
2004-02-10 |
International Paper Company |
Automated bulk box strapper
|
US7318928B2
(en)
*
|
2000-08-01 |
2008-01-15 |
The Johns Hopkins University |
Molecular vaccine linking intercellular spreading protein to an antigen
|
GB0022101D0
(en)
*
|
2000-09-08 |
2000-10-25 |
Phogen Ltd |
Delivery of substances to cells
|
US6472176B2
(en)
*
|
2000-12-14 |
2002-10-29 |
Genvec, Inc. |
Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
|
GB0112818D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Lorantis Ltd |
Conjugate
|
EP2191845A1
(en)
|
2001-07-31 |
2010-06-02 |
University of Washington |
Immunology significant herpes simplex virus antigens and methods for using same
|
WO2003042239A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Stichting Sanquin Bloedvoorziening |
Peptides inhibiting signaling by ras-like gtpases
|
CA2486449A1
(en)
*
|
2002-05-17 |
2004-02-19 |
Automated Cell, Inc. |
Determination of protein function
|
WO2004009027A2
(en)
*
|
2002-07-19 |
2004-01-29 |
Myriad Genetics, Inc |
Method and composition for treating and preventing herpesvirus infection
|
AU2003267124A1
(en)
|
2002-09-09 |
2004-03-29 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
AU2004204456A1
(en)
*
|
2003-01-09 |
2004-07-29 |
Invitrogen Corporation |
Cellular delivery and activation polypeptide-nucleic acid complexes
|
IL157787A
(en)
*
|
2003-09-07 |
2010-12-30 |
Mosaid Technologies Inc |
Modular outlet for data communications network
|
ITRM20030376A1
(it)
|
2003-07-31 |
2005-02-01 |
Univ Roma |
Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
|
GB0321311D0
(en)
*
|
2003-09-12 |
2003-10-15 |
Phogen Ltd |
Delivery of substances to cells
|
US11660317B2
(en)
|
2004-11-08 |
2023-05-30 |
The Johns Hopkins University |
Compositions comprising cardiosphere-derived cells for use in cell therapy
|
ATE483158T1
(de)
|
2005-04-05 |
2010-10-15 |
Allergan Inc |
Clostridientoxinaktivitätstests
|
US8080517B2
(en)
|
2005-09-12 |
2011-12-20 |
Xigen Sa |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
WO2007031098A1
(en)
|
2005-09-12 |
2007-03-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
US20090227032A1
(en)
*
|
2005-12-13 |
2009-09-10 |
Kyoto University |
Nuclear reprogramming factor and induced pluripotent stem cells
|
EP2208786B1
(en)
|
2005-12-13 |
2018-08-01 |
Kyoto University |
Nuclear reprogramming factor
|
US8278104B2
(en)
|
2005-12-13 |
2012-10-02 |
Kyoto University |
Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
|
US8129187B2
(en)
|
2005-12-13 |
2012-03-06 |
Kyoto University |
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
|
CN101374860A
(zh)
|
2005-12-23 |
2009-02-25 |
技术转让合伙人公司 |
用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
|
JP2009532033A
(ja)
|
2006-03-31 |
2009-09-10 |
ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド |
細胞の化学感受性を定量する方法
|
WO2008021484A2
(en)
|
2006-08-16 |
2008-02-21 |
Eutropics Pharmaceuticals |
Assay system to identify therapeutic agents
|
JP2008307007A
(ja)
*
|
2007-06-15 |
2008-12-25 |
Bayer Schering Pharma Ag |
出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
|
US9213999B2
(en)
|
2007-06-15 |
2015-12-15 |
Kyoto University |
Providing iPSCs to a customer
|
GB0724253D0
(en)
*
|
2007-12-12 |
2008-01-30 |
Fermentas Uab |
Transfection reagent
|
ES2722198T3
(es)
*
|
2008-05-02 |
2019-08-08 |
Univ Kyoto |
Método de reprogramación nuclear
|
WO2009143864A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
|
WO2009143865A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
WO2010072228A1
(en)
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
US8460674B2
(en)
|
2009-02-07 |
2013-06-11 |
University Of Washington |
HSV-1 epitopes and methods for using same
|
EP2413950A4
(en)
|
2009-04-03 |
2013-05-01 |
Univ Washington |
ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
|
GB0917792D0
(en)
*
|
2009-10-12 |
2009-11-25 |
Fermentas Uab |
Delivery agent
|
US9856456B2
(en)
|
2009-10-12 |
2018-01-02 |
Thermo Fisher Scientific Baltics Uab |
Delivery agent
|
DK2547771T3
(da)
*
|
2010-03-18 |
2017-01-16 |
Spiber Tech Ab |
Fremstilling af proteiner og polypeptider
|
US9845457B2
(en)
|
2010-04-30 |
2017-12-19 |
Cedars-Sinai Medical Center |
Maintenance of genomic stability in cultured stem cells
|
WO2011160653A1
(en)
|
2010-06-21 |
2011-12-29 |
Xigen S.A. |
Novel jnk inhibitor molecules
|
WO2012006440A2
(en)
|
2010-07-07 |
2012-01-12 |
Cellular Dynamics International, Inc. |
Endothelial cell production by programming
|
PL2902035T3
(pl)
|
2010-10-14 |
2019-04-30 |
Xigen Inflammation Ltd |
Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
|
JP5857056B2
(ja)
|
2010-10-14 |
2016-02-10 |
ザイジェン インフラメーション エルティーディー |
慢性又は非慢性の炎症性眼疾患を治療するためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
|
US9127283B2
(en)
|
2010-11-24 |
2015-09-08 |
Clontech Laboratories, Inc. |
Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
|
EP2673358B1
(en)
|
2011-02-08 |
2019-01-09 |
FUJIFILM Cellular Dynamics, Inc. |
Hematopoietic precursor cell production by programming
|
BR112014013041A2
(pt)
|
2011-11-30 |
2019-09-24 |
Xigen Inflammation Ltd |
uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
|
WO2013091670A1
(en)
|
2011-12-21 |
2013-06-27 |
Xigen S.A. |
Novel jnk inhibitor molecules for treatment of various diseases
|
WO2013184527A1
(en)
|
2012-06-05 |
2013-12-12 |
Capricor, Inc. |
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
|
JP6433896B2
(ja)
|
2012-08-13 |
2018-12-05 |
シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center |
組織再生のためのエキソソームおよびマイクロリボ核酸
|
CA2885230C
(en)
|
2012-09-19 |
2021-08-03 |
Anthony Letai |
Dynamic bh3 profiling
|
WO2014206427A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
WO2015197098A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
WO2014206426A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use for jnk inhibitor molecules for treatment of various diseases
|
WO2015197097A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use for jnk inhibitor molecules for treatment of various diseases
|
WO2016055160A2
(en)
|
2014-10-08 |
2016-04-14 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
US10624948B2
(en)
|
2013-06-26 |
2020-04-21 |
Xigen Inflammation Ltd. |
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
|
WO2015042249A1
(en)
|
2013-09-19 |
2015-03-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
EP3169310A1
(en)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
AU2015327812B2
(en)
|
2014-10-03 |
2021-04-15 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
US20180120297A1
(en)
|
2015-04-27 |
2018-05-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for assessing toxicity using dynamic bh3 profiling
|
ES2921350T3
(es)
|
2015-05-18 |
2022-08-24 |
Sumitomo Pharma Oncology Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
US11253551B2
(en)
|
2016-01-11 |
2022-02-22 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
|
WO2017210652A1
(en)
|
2016-06-03 |
2017-12-07 |
Cedars-Sinai Medical Center |
Cdc-derived exosomes for treatment of ventricular tachyarrythmias
|
WO2018057542A1
(en)
|
2016-09-20 |
2018-03-29 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
EP3612191A4
(en)
|
2017-04-19 |
2020-12-30 |
Cedars-Sinai Medical Center |
METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
US11660355B2
(en)
|
2017-12-20 |
2023-05-30 |
Cedars-Sinai Medical Center |
Engineered extracellular vesicles for enhanced tissue delivery
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
WO2022157548A1
(en)
|
2021-01-24 |
2022-07-28 |
Forrest Michael David |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|